45 reports

  • ND0611 DERMAL PATCH - PRODUCT DESCRIPTION
  • AQS1304 - PRODUCT DESCRIPTION

OFTEN, THIS PROMOTES HEALING TO AN INJURED AREA OF THE BODY. ##. ## TRANSDERMAL DRUG DELIVERY DEVICES - PIPELINE PRODUCTS BY STAGE OF DEVELOPMENT FIGURE ##: TRANSDERMAL DRUG DELIVERY DEVICES - PIPELINE PRODUCTS BY STAGE OF DEVELOPMENT ## Products under Develop

  • Clinical Trial
  • Mental Health
  • Pharmaceutical
  • United States
  • Company
  • TRANSDERMAL PATCH - PARKINSON'S DISEASE - PRODUCT STATUS
  • AQS1304 - PRODUCT DESCRIPTION

Often, this promotes healing to an injured area of the body. ##. ## TRANSDERMAL DRUG DELIVERY - PIPELINE PRODUCTS BY STAGE OF DEVELOPMENT FIGURE ##: TRANSDERMAL DRUG DELIVERY - PIPELINE PRODUCTS BY STAGE OF DEVELOPMENT ## Products under Development TABLE

  • Mental Health
  • Therapy
  • United States
  • Company
  • Aequus Pharmaceuticals Inc.
  • ASENAPINE MALEATE - DRUG PROFILE
  • Sep 27, 2018: Luye Pharma Further Bolsters Global CNS Portfolio with Approval to Start LY03010 U.S. Clinical Trials

The investigational product is a transdermal formulation developed using Transdermal Drug Delivery System (TDDS) technology.

  • Mental Health
  • Psychotic Disorder
  • United States
  • Company
  • Product Initiative
  • Application
  • Indication

Additionally, one subject fell and fractured his nose, and there was one case of suspected panniculitis that was eventually ruled out.

  • Mental Health
  • Europe
  • Company Operations
  • Product Initiative
  • NeuroDerm Ltd.
  • ZYNERBA PRODUCT PIPELINE
  • 6.2 Zynerba

Whereas, ZYN## is a pro-drug of THC that enables effective transdermal delivery of THC via a patch and is patent protected through 2031.

  • Mental Health
  • Europe
  • United States
  • World
  • GW Pharmaceuticals plc

Its ZYN## is a synthetic CBD, a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery.

  • Antiseptics
  • Mental Health
  • Pharmaceutical
  • United States
  • Product Initiative
  • Restless Legs Syndrome - Product Development Milestones
  • Restless Legs Syndrome - Product Development Milestones

The product is a systemic transdermal tape formulation developed by utilizing Hisamitsu' s TDDS (Transdermal Drug Delivery System) technology.

  • Mental Health
  • Neurological Disorder
  • United States
  • Product Initiative
  • Relmada Therapeutics, Inc.
  • R&D Progress

It is applied as a transdermal patch.

  • Mental Health
  • Neurological Disorder
  • United States
  • Product Initiative
  • KemPharm, Inc.
  • SMALL MOLECULE TO TARGET CALCIUM ACTIVATED POTASSIUM CHANNEL, KOR1, AND MOR1 FOR CHRONIC PAIN AND OPIOID DEPENDENCE - DRUG PROFILE

Zynerba Pharmaceuticals' s ZYN##, is a pro-drug of THC which enables the transdermal delivery through skin and into the circulatory system via patch.

  • Mental Health
  • Opioid
  • United States
  • Product Initiative
  • Addex Therapeutics Ltd

Friend was vice president of research at Vyteris, a company that develops novel transdermal delivery systems.

  • Clinical Trial
  • HIV AIDS
  • Mental Health
  • United States
  • AcelRx Pharmaceuticals, Inc.
  • EPILEPSY - PIPELINE BY ZYNERBA PHARMACEUTICALS INC, H2 2018
  • CLOBAZAM ER - DRUG PROFILE

It is developed based on transdermal drug delivery technology.

  • Mental Health
  • United States
  • Company
  • Product Initiative
  • Anavex Life Sciences Corp.
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Drug Profiles

The invention discloses the compositions that are useful in effecting the transdermal delivery of Mechanism Of Action Discovery/ Preclinical Trial Details Phase I - Trial Details Phase II - Trial Details ##-Nov-2010 Other Developmental Activities active agents such as opipramol

  • Mental Health
  • Therapy
  • World
  • Product Initiative
  • Suven Life Sciences Ltd

The invention discloses the compositions that are useful in effecting the transdermal delivery of Mechanism Of Action Discovery/ Preclinical Trial Details Phase I - Trial Details Phase II - Trial Details ##-Nov-2010 Other Developmental Activities active agents such as opipramol

  • Mental Health
  • Therapy
  • World
  • Product Initiative
  • Suven Life Sciences Ltd
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Mental Health
  • Neurological Disorder
  • Therapy
  • World
  • Product Initiative

BUYER' S POWER - Moderate ##.

  • Mental Health
  • Pathology
  • World
  • Cardinal Health, Inc.
  • Eckert & Ziegler AG
  • Indication Name
  • DRUG ADDICTION - PIPELINE BY ZYNERBA PHARMACEUTICALS INC, H1 2019

Its ZYN## is a synthetic CBD, a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery.

  • Addiction Disorder
  • Mental Health
  • United States
  • Product Initiative
  • MediciNova, Inc.
  • ENCEPHALOPATHY - PIPELINE BY SCIFLUOR LIFE SCIENCES LLC, H1 2018
  • ENCEPHALOPATHY - PIPELINE BY TAKEDA PHARMACEUTICAL CO LTD, H1 2018

Zynerba Pharmaceuticals' s ZYN##, is a pro-drug of THC which enables the transdermal delivery through skin and into the circulatory system via patch.

  • Mental Health
  • Neurological Disorder
  • Pharmaceutical
  • United States
  • Product Initiative

LTS advances emerging drug delivery technologies such as micro array patches for the transdermal delivery of large molecule biological actives.

  • Mental Health
  • Pharmaceutical
  • United States
  • Company
  • Intec Pharma Ltd.

Its ZYN## is a synthetic CBD, a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery.

  • Drug Development
  • Mental Health
  • United States
  • Product Initiative
  • MediciNova, Inc.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Depression
  • Mental Health
  • World
  • Product Initiative

It also provides ProTek, a protein stabilization technology to create homogeneous, stable, aqueous or lyophilized dosage forms for peptide or protein therapeutics; and Aegis Hydrogel, a proprietary absorption-enhancing self-assembling aqueous hydrogels useful for transdermal drug

  • Mental Health
  • Pharmaceutical
  • United States
  • Company
  • Opiant Pharmaceuticals, Inc.
  • Clinical Trial Profile Snapshots
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Drug Development
  • Mental Health
  • World
  • Product Initiative
  • Jan 31, 2018: Notification of the Results of the Phase III Clinical Study of HP-3070 (Transdermal Patch for the Treatment of Schizophrenia) in the U.S.
  • ASENAPINE MALEATE - DRUG PROFILE

The investigational product is a transdermal formulation developed using Transdermal Drug Delivery System (TDDS) technology.

  • Mental Health
  • United States
  • Company
  • Product Initiative
  • Omeros Corporation
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • Mental Health
  • World
  • Pfizer Inc.
  • Jan 03, 2018: Zynerba Pharmaceuticals Provides Update on cannabidiol

Zynerba Pharmaceuticals' s ZYN##, is a pro-drug of THC which enables the transdermal delivery through skin and into the circulatory system via patch.

  • Mental Health
  • Therapy
  • United States
  • Product Initiative
  • Anavex Life Sciences Corp.
  • NEURODEGENERATIVE DISEASE DRUGS MARKET, GLOBAL, APPROVED INDICATIONS FOR NEUPRO, 2018

Neupro is the only non-ergot DA in the current market that uses a transdermal delivery system.

  • Mental Health
  • Therapy
  • Company
  • Company Financials
  • Forecast
  • TF-0066 - DRUG PROFILE

IT IS DEVELOPED BASED ON TRANSDERMAL DRUG DELIVERY TECHNOLOGY.

  • Mental Health
  • United States
  • Company
  • Product Initiative
  • Anavex Life Sciences Corp.
  • DEXTROAMPHETAMINE - DRUG PROFILE
  • ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) - PIPELINE BY OTSUKA HOLDINGS CO LTD, H2 2018

It advances patient care through transdermal drug delivery.

  • Mental Health
  • Neurological Disorder
  • Pharmaceutical
  • United States
  • Product Initiative

IT IS DEVELOPED BASED ON TRANSDERMAL DRUG DELIVERY TECHNOLOGY.

  • Chronic Pain
  • Mental Health
  • Pharmaceutical
  • Therapy
  • Can-Fite BioPharma Ltd.

IT IS AN INCREMENTALLY MODIFIED DRUG ADMINISTERED BY TRANSDERMAL ROUTE.

  • Mental Health
  • Monoclonal Antibody
  • United States
  • Company
  • Product Initiative